goserelin and Cushing-Syndrome

goserelin has been researched along with Cushing-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for goserelin and Cushing-Syndrome

ArticleYear
Final adult height and body mass index after cure of paediatric Cushing's disease.
    Clinical endocrinology, 2005, Volume: 62, Issue:4

    Linear growth data after cure of paediatric Cushing's disease (CD) have been reported infrequently. We evaluated final adult height (FH) and body mass index (BMI) in a cohort of paediatric patients treated successfully for CD.. Fourteen patients (10 male, age range 6.4-16.6 years) fulfilled the diagnostic criteria for CD. All had had transsphenoidal surgery (TSS), combined with pituitary irradiation (RT) (45 Gy in 25 fractions) in six. All were cured (post-TSS cortisol < 50 nmol/l or mean cortisol post-RT < 150 nmol/l). Subjects analysed had bone ages at diagnosis of < 15 'years' (male) and < 13 'years' (female).. At diagnosis, height SDS was [mean (range)]-2.5 (-4.2 to -0.8) and body mass index (BMI) SDS +2.7 (0.8-5.1). Following cure, 13 patients had GH deficiency (peak GH < 20 mU/l) and were treated with hGH (+ GnRH analogue in four). Height SDS at FH (n = 10) or latest assessment (n = 4) was -1.3 (-3.9-0.2) and increased compared to diagnosis (P < 0.01). The difference between final or latest height SDS and target height SDS was -1.2 (-3.3-0.5), that is less (P < 0.01) than the difference between the height SDS at diagnosis and target height SDS of -2.4 (-3.9 to -0.5). At final height or latest assessment, BMI SDS was +1.7 (0.4-6.2), being decreased compared to diagnosis (P < 0.05) but greater than the normal population (P < 0.01).. Catch-up growth was demonstrated in paediatric patients cured from CD, with the majority achieving FH within target height range. Early diagnosis and treatment of GH deficiency is recommended to achieve optimal long-term growth. Excess adiposity remains a potential long-term complication.

    Topics: Adolescent; Body Height; Body Mass Index; Child; Cushing Syndrome; Female; Gonadotropin-Releasing Hormone; Goserelin; Human Growth Hormone; Humans; Male; Pituitary Gland; Pituitary Irradiation; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome

2005
Acceleration of pubertal development following pituitary radiotherapy for Cushing's disease.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1993, Volume: 5, Issue:6

    A 7-year-old boy with pituitary dependent Cushing's disease was treated with pituitary irradiation following unsuccessful microadenomectomy. This led to normalization of the hypercortisolaemia, but was followed by GH deficiency. Two years after radiotherapy he had the onset of pubertal development with testicular enlargement to 8 ml bilaterally. Pubertal regression was induced using the long-acting GnRH analogue goserelin. Acceleration of skeletal maturation was also arrested, resulting in improvement of final height prediction. Irradiation directly to the hypothalamo-pituitary region, as well as whole brain irradiation, may thus be associated with accelerated pubertal development.

    Topics: Child; Cushing Syndrome; Goserelin; Humans; Male; Pituitary Gland; Puberty; Puberty, Precocious

1993